Entering text into the input field will update the search result below

Vyxeos receives marketing authorisation in the European Union for treatment of AML

  • Jazz Pharmaceuticals (NASDAQ:JAZZ) announces that the European Commission approved Vyxeos 44 mg/100 mg powder for concentrate for solution for infusion for the treatment of adults with therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
  • Vyxeos is an advanced liposomal formulation that delivers a synergistic molar ratio of daunorubicin and cytarabine.
  • Vyxeos is the first chemotherapy to demonstrate an overall survival advantage versus the standard of care in a Phase 3 study of older adult patients with newly diagnosed t-AML or AML-MRC.

Recommended For You

More Trending News

About JAZZ Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
JAZZ--
Jazz Pharmaceuticals plc